LNTH

MKT CAP:$5B

Lantheus Holdings, Inc.

Market Cap

$5B

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NASDAQ

Healthcare·Drug·🇺🇸·NASDAQ

Stock Price

$84.00+$16.73 (+24.86%)

Apr 20, 2026

Company Details

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble...

CEO

Mary Anne Heino

IPO Date

Jun 25, 2015

Website

www.lantheus.com

Key Metrics TTM

Revenue

$1.5B

+0.5% YoY

Net Income

$234M

EPS (Diluted)

$3.37

Free Cash Flow

$349M

Revenue / Share

$23.25

Gross Margin

61.1%

Operating Margin

20.2%

Net Margin

15.2%

FCF Margin

22.6%

P/S

3.6x

P/E

23.5x

Earnings Reports

Q1 2026

May 6, 2026

PENDING

FY 2025

Feb 26, 2026

$1.5B+0.5%EPS $3.41

Q4 2025

Feb 26, 2026

$407M+4.0%EPS $0.82

Q3 2025

Nov 6, 2025

$384M+1.4%EPS $0.41

Q2 2025

Aug 6, 2025

$378M-4.1%EPS $1.12

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$209M	$129M	$59M
Q2 22	$224M	$138M	$63M
Q3 22	$239M	$147M	$86M
Q4 22	$263M	$167M	-$172M
Q1 23	$301M	$77M	-$9M
Q2 23	$322M	$203M	$124M
Q3 23	$320M	$200M	$112M
Q4 23	$354M	$230M	$137M
Q1 24	$370M	$252M	$100M
Q2 24	$394M	$256M	$103M
Q3 24	$379M	$242M	$134M
Q4 24	$391M	$249M	$114M
Q1 25	$373M	$238M	$102M
Q2 25	$378M	$241M	$88M
Q3 25	$384M	$222M	$44M
Q4 25	$407M	$241M	$77M

Valuation

Quarter	P/S	P/E
Q1 22	6.6x	—
Q2 22	6.8x	139.6x
Q3 22	6.4x	47.7x
Q4 22	3.5x	115.3x
Q1 23	5.5x	—
Q2 23	5.1x	171.8x
Q3 23	3.8x	44.5x
Q4 23	3.5x	13.7x
Q1 24	3.0x	9.0x
Q2 24	3.8x	12.8x
Q3 24	5.1x	17.8x
Q4 24	4.0x	19.8x
Q1 25	4.4x	26.6x
Q2 25	3.7x	20.7x
Q3 25	2.3x	20.7x
Q4 25	2.9x	19.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	$10M	$7M
Q2 22	$73M	$68M
Q3 22	$94M	$87M
Q4 22	$105M	$101M
Q1 23	$109M	$99M
Q2 23	-$32M	-$43M
Q3 23	$117M	$102M
Q4 23	$112M	$100M
Q1 24	$127M	$119M
Q2 24	$85M	$74M
Q3 24	$175M	$159M
Q4 24	$155M	$139M
Q1 25	$108M	$99M
Q2 25	$87M	$74M
Q3 25	$105M	$95M
Q4 25	$90M	$81M

Capital Expenditures

Quarter	CapEx
Q1 22	$3M
Q2 22	$4M
Q3 22	$6M
Q4 22	$5M
Q1 23	$9M
Q2 23	$11M
Q3 23	$15M
Q4 23	$12M
Q1 24	$8M
Q2 24	$11M
Q3 24	$16M
Q4 24	$16M
Q1 25	$9M
Q2 25	$13M
Q3 25	$11M
Q4 25	$9M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	+125.8%	+95.0%
Q2 22	+121.4%	+25.6%
Q3 22	+134.4%	+31.9%
Q4 22	+103.1%	+163.7%
Q1 23	+44.0%	+106.8%
Q2 23	+43.8%	+23.1%
Q3 23	+33.7%	+35.2%
Q4 23	+34.5%	-50.2%
Q1 24	+23.0%	-13.1%
Q2 24	+22.5%	+47.5%
Q3 24	+18.4%	+18.0%
Q4 24	+10.5%	+28.0%
Q1 25	+0.8%	+0.4%
Q2 25	-4.1%	-0.4%
Q3 25	+1.4%	+38.9%
Q4 25	+4.0%	+18.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$6M	2.7%
Q2 22	$0	0.0%
Q3 22	$8M	3.4%
Q4 22	$0	0.0%
Q1 23	$10M	3.2%
Q2 23	$0	0.0%
Q3 23	$14M	4.4%
Q4 23	$0	0.0%
Q1 24	$15M	4.2%
Q2 24	$0	0.0%
Q3 24	$0	0.0%
Q4 24	$0	0.0%
Q1 25	$21M	5.7%
Q2 25	$22M	5.9%
Q3 25	$0	0.0%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 22	$12M	$38M	$20M
Q2 22	$15M	$33M	$27M
Q3 22	$13M	$24M	$25M
Q4 22	$272M	$40M	$27M
Q1 23	$31M	$23M	$33M
Q2 23	$16M	$26M	$36M
Q3 23	$14M	$36M	$37M
Q4 23	$17M	$40M	$35M
Q1 24	$48M	$48M	$46M
Q2 24	$61M	$47M	$45M
Q3 24	$24M	$41M	$44M
Q4 24	$35M	$58M	$44M
Q1 25	$36M	$57M	$43M
Q2 25	$45M	$67M	$41M
Q3 25	$48M	$82M	$49M
Q4 25	$47M	$70M	$46M

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$105M	$0	$105M
Q2 22	$171M	$0	$171M
Q3 22	$257M	$0	$257M
Q4 22	$416M	$0	$416M
Q1 23	$471M	$0	$471M
Q2 23	$414M	$0	$414M
Q3 23	$614M	$0	$614M
Q4 23	$714M	$0	$714M
Q1 24	$718M	$0	$718M
Q2 24	$757M	$0	$757M
Q3 24	$866M	$0	$866M
Q4 24	$913M	$0	$913M
Q1 25	$939M	$0	$939M
Q2 25	$696M	$0	$696M
Q3 25	$382M	$0	$382M
Q4 25	$359M	$0	$359M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	70M	+3.5%	+3.5%
Q2 22	71M	+1.1%	+4.9%
Q3 22	71M	+0.4%	+5.1%
Q4 22	69M	-3.6%	+1.2%
Q1 23	68M	-1.1%	-3.3%
Q2 23	71M	+4.8%	+0.3%
Q3 23	70M	-1.4%	-1.4%
Q4 23	70M	+0.1%	+2.3%
Q1 24	70M	+0.0%	+3.5%
Q2 24	71M	+0.7%	-0.6%
Q3 24	73M	+3.5%	+4.3%
Q4 24	69M	-5.3%	-1.2%
Q1 25	71M	+3.2%	+1.9%
Q2 25	70M	-1.6%	-0.4%
Q3 25	68M	-3.8%	-7.4%
Q4 25	66M	-2.0%	-4.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$341.3K	612
Q2 22	$365.6K	612
Q3 22	$391.0K	612
Q4 22	$377.0K	698
Q1 23	$430.9K	698
Q2 23	$460.9K	698
Q3 23	$458.4K	698
Q4 23	$424.5K	834
Q1 24	$443.6K	834
Q2 24	$472.5K	834
Q3 24	$454.1K	834
Q4 24	$484.0K	808
Q1 25	$461.3K	808
Q2 25	$467.9K	808
Q3 25	$475.3K	808
Q4 25	$2.0K	200K

Revenue / Employee